BioShield II May Revive Big Pharma’s Interest In Biodefense
Executive Summary
The proposed "BioShield II" legislation is reviving big pharma's interest in the biodefense industry, McKenna Long & Aldridge Partner Frank Rapoport maintained March 3 at Equity International's Homeland & Global Security Summit in Washington, D.C
You may also be interested in...
Pfizer Names Bush Cabinet Veteran Principi To Head Government Affairs
Former Veterans Affairs Secretary Anthony Principi will replace Pfizer VP-Government Relations Kenneth Bowler as head of the company's government affairs staff effective March 15
Pfizer Names Bush Cabinet Veteran Principi To Head Government Affairs
Former Veterans Affairs Secretary Anthony Principi will replace Pfizer VP-Government Relations Kenneth Bowler as head of the company's government affairs staff effective March 15
FDA “Rapid-Action” Team, Pre-Emption Included In GOP Bioterror Bill
The Senate leadership's biodefense bill for 2005 would direct FDA to create a special compliance unit to help prevent shortages of vaccines
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: